News Sentiment

EXEL sentiment intelligence

Exelixis Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 69 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 51.91 Week of 19 Jun 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 62

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-2.3% over one week, +3.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Exelixis Stock - weekly review and biotech sector context

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction -2.3% Price reacting lower
Trend fit Trend active 3.5% over four weeks
Fair value 59.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 36
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 62
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 15
simplywall.st 6
MarketBeat 6
Stock Titan 6
AD HOC NEWS 4
TradingKey 4
Investing.com 3
Business Wire 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 31
Regulatory and legal 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 69
TradingKey Direct company coverage

Exelixis Inc (EXEL) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Exelixis Inc (EXEL), highlighting its current earnings forecast score, analyst ratings, and price targets. It details expected EPS and revenue for upcoming quarters and compares EXEL's analyst ratings to its peers in the Biotechnolog

Tone
Positive 66/100
Event
Earnings
Published
18 Jun 2026 09:10
Source
TradingKey
TradingKey Direct company coverage

Exelixis Inc (EXEL) Financial Health: Profitability & Balance Sheet Analysis

Exelixis Inc (EXEL) demonstrates robust financial health with a score of 8.96, ranking 21st in the Biotechnology & Medical Research industry. The company reported a significant year-over-year revenue increase of 9.97% to $610.81M and a net profit increase of 31.86%. This strong p

Tone
Positive 70/100
Event
Earnings
Published
18 Jun 2026 06:10
Source
TradingKey
TradingKey Direct company coverage

Exelixis Inc (EXEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Exelixis Inc (EXEL), categorizing its income by business segments and geographical regions. As of April 6, 2025, CABOMETYX is the primary revenue driver, contributing 91.09% of the total, with the U.S. market dominating regio

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 08:41
Source
TradingKey
TradingKey Direct company coverage

Exelixis Inc (EXEL) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Exelixis Inc's (EXEL) shareholder structure, listing major institutional holders and their proportion of shares. It details shareholder types, institutional shareholding trends over recent quarters, and individual shareholder activity with cha

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 08:41
Source
TradingKey
AD HOC NEWS Direct company coverage

Exelixis Inc Stock (US30161Q1040): Quarterly earnings in focus after recent results

Exelixis Inc reported its first-quarter 2024 financial results, showing revenue growth driven primarily by its flagship cancer drug, Cabometyx. The company also provided an updated 2024 financial outlook, projecting continued revenue growth despite increased R&D spending to furth

Tone
Positive 72/100
Event
Earnings
Published
15 Jun 2026 14:09
Source
AD HOC NEWS
Stock Traders Daily Direct company coverage

Why (EXEL) Price Action Is Critical for Tactical Trading

This article from Stock Traders Daily discusses the critical price action of Exelixis Inc. (NASDAQ: EXEL) for tactical trading, based on AI-driven analysis. It highlights strong sentiment across all time horizons, indicating an overweight bias, and identifies potential upside. Th

Tone
Positive 72/100
Event
Market update
Published
15 Jun 2026 04:04
Source
Stock Traders Daily
Market source Direct company coverage

Exelixis CABINET Win Extends CABOMETYX Reach And Raises Valuation Questions

Exelixis reported positive phase 3 CABINET trial results for CABOMETYX in advanced neuroendocrine tumors, demonstrating significant improvement in progression-free survival. This extends the potential reach of CABOMETYX, but given the stock's strong performance, investors are eva

Tone
Positive 70/100
Event
Earnings
Published
13 Jun 2026 20:08
Source
Market source
MarketBeat Direct company coverage

Goldman Sachs Group Inc. Purchases 1,113,916 Shares of Exelixis, Inc. $EXEL

Goldman Sachs Group Inc. significantly increased its stake in Exelixis, Inc. (NASDAQ:EXEL) during the fourth quarter, purchasing over 1.1 million additional shares, raising its total holding to 2.1 million shares valued at approximately $92.7 million. Following this news, Exelixi

Tone
Positive 71/100
Event
Earnings
Published
11 Jun 2026 03:39
Source
MarketBeat
MarketBeat Direct company coverage

Cibc World Market Inc. Purchases 31,985 Shares of Exelixis, Inc. $EXEL

Cibc World Market Inc. significantly increased its stake in Exelixis, Inc. by 462.3% in the fourth quarter, adding 31,985 shares to hold a total of 38,904 shares valued at $1.705 million. This move is part of a broader trend, with other institutional investors also boosting their

Tone
Positive 71/100
Event
Earnings
Published
10 Jun 2026 16:39
Source
MarketBeat
MarketBeat Direct company coverage

BI Asset Management Fondsmaeglerselskab A S Has $1.91 Million Position in Exelixis, Inc. $EXEL

BI Asset Management Fondsmaeglerselskab A S significantly reduced its stake in Exelixis, Inc. by 74.9% in the fourth quarter, now holding 43,658 shares valued at approximately $1.91 million. This comes as several insiders, including CFO Christopher J. Senner and Director Sue Gail

Tone
Neutral 50/100
Event
Earnings
Published
10 Jun 2026 15:39
Source
MarketBeat
MarketBeat Direct company coverage

Bank of New York Mellon Corp Cuts Position in Exelixis, Inc. $EXEL

Bank of New York Mellon Corp reduced its stake in Exelixis, Inc. by 12.3% during the fourth quarter, selling 285,584 shares. Despite this, other institutional investors like Goldman Sachs Group Inc. and BNP Paribas Financial Markets increased their holdings significantly. Exelixi

Tone
Positive 60/100
Event
Earnings
Published
10 Jun 2026 03:39
Source
MarketBeat
Investing.com Nigeria Direct company coverage

Exelixis stock hits all-time high at 52.98 USD By Investing.com

Exelixis Inc. (EXEL) stock reached an all-time high of $52.98, reflecting a 24.86% increase over the past year. The biotechnology company, currently valued at $13.34 billion, shows an attractive P/E ratio of 17.08 and a PEG ratio of 0.42, suggesting undervaluation and strong near

Tone
Positive 74/100
Event
Market update
Published
09 Jun 2026 14:41
Source
Investing.com Nigeria
MarketBeat Direct company coverage

Exelixis, Inc. $EXEL Position Increased by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. significantly increased its stake in Exelixis, Inc. by 2,920.5% in the fourth quarter, now owning 25,040 shares valued at $1.1 million. This increase comes as Exelixis reported strong quarterly results, beating EPS estimates with $0.87 an

Tone
Neutral 50/100
Event
Earnings
Published
09 Jun 2026 04:10
Source
MarketBeat
DirectorsTalk Interviews Direct company coverage

Exelixis, Inc. (EXEL) Stock Analysis: A Promising Player in Biotechnology with Strong Revenue Growth

Exelixis, Inc. (EXEL) is highlighted as a significant player in the biotechnology sector, specializing in cancer treatments with products like CABOMETYX and COMETRIQ. The company demonstrates strong financial performance with 10% year-over-year revenue growth and a High ROE of 40

Tone
Positive 72/100
Event
Earnings
Published
08 Jun 2026 10:14
Source
DirectorsTalk Interviews
Sahm Direct company coverage

CABINET Results Broaden CABOMETYX Neuroendocrine Reach And Investor Considerations

Exelixis, Inc. reported new phase 3 CABINET trial data for CABOMETYX in advanced neuroendocrine tumors, showing significant improvements in progression-free survival regardless of tumor functional status. These results expand the clinical evidence for CABOMETYX and reinforce its

Tone
Positive 71/100
Event
Earnings
Published
07 Jun 2026 01:39
Source
Sahm
Investing.com Direct company coverage

Exelixis director Sue Eckhardt sells $491,973 in stock

Exelixis director Sue Eckhardt sold 9,812 shares of the company's common stock for $491,973 on June 1, 2026, as part of a Rule 10b5-1 trading plan. The sale occurred while the stock was near its 52-week high, though InvestingPro analysis suggests it is still undervalued with exce

Tone
Negative 41/100
Event
Market update
Published
04 Jun 2026 13:40
Source
Investing.com
Investing.com Direct company coverage

Exelixis director Jack Wyszomierski sells $198,408 in shares

Jack L. Wyszomierski, a director at Exelixis Inc. (NASDAQ:EXEL), recently sold 3,925 shares of the company's common stock for $198,408. This transaction was executed under a Rule 10b5-1 trading plan. The article also notes Exelixis' strong financial performance in Q1 2026 and its

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 12:40
Source
Investing.com
Intellectia AI Direct company coverage

EXEL Financials: Revenue Breakdown, Margins & Competitor Comparison

This article provides a detailed financial analysis of Exelixis Inc (EXEL), outlining its revenue breakdown, profitability margins, and a comparison with key competitors RGC and MDGL. It highlights that CABOMETYX is the primary revenue driver, contributing 90.3% of total sales, a

Tone
Neutral 50/100
Event
Earnings
Published
04 Jun 2026 04:39
Source
Intellectia AI
Stock Titan Direct company coverage

[144] EXELIXIS, INC. SEC Filing

This SEC filing refers to a Form 144 filed by Exelixis, Inc. (EXEL) on June 1, 2026, indicating a proposed sale of securities. The document outlines the information required for such a sale under Rule 144, including details about the securities to be sold (9812 shares of common s

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 03:09
Source
Stock Titan
GuruFocus Direct company coverage

Insider Sell Alert: Jack Wyszomierski Sells 3,925 Shares of Exelixis Inc (EXEL)

Jack Wyszomierski, a Director at Exelixis Inc (EXEL), sold 3,925 shares of the company on June 1, 2026, increasing his total sales over the past year to 103,499 shares. Exelixis, a biotechnology company focused on cancer treatments, has seen 1 insider buy and 21 insider sells in

Tone
Negative 37/100
Event
Market update
Published
04 Jun 2026 00:11
Source
GuruFocus
Stock Titan Direct company coverage

Planned share sale by Exelixis (NASDAQ: EXEL) director Wyszomierski

Exelixis director Jack L. Wyszomierski sold 3,925 shares of common stock at $50.55 per share on June 1, 2026. This transaction was part of a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following the sale, he directly holds 284,384 shares, with an additional 8,

Tone
Negative 40/100
Event
Market update
Published
03 Jun 2026 23:10
Source
Stock Titan
Stock Titan Direct company coverage

Exelixis (EXEL) director Eckhardt sells 9,812 shares under 10b5-1 plan

Exelixis (EXEL) director Sue Gail Eckhardt sold 9,812 shares of common stock at a weighted average price of $50.14 per share on June 1, 2026, under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, her total holdings include 16,079 shares, which account for rest

Tone
Negative 39/100
Event
Market update
Published
03 Jun 2026 23:10
Source
Stock Titan
AlphaStreet Direct company coverage

Exelixis Jumps 5.0% Amid Sector-Wide Rally

Exelixis, Inc. saw its stock price surge by 5.0% to $50.99 on Wednesday, driven by a broader rally in the biotechnology sector. This rise, which included similar gains for several peer companies like Incyte and Moderna, was attributed to sector-wide momentum rather than any speci

Tone
Positive 73/100
Event
Market update
Published
03 Jun 2026 17:10
Source
AlphaStreet